ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
Record Q2 revenue ₹773 Cr (+13.9%), EBITDA ₹212 Cr (+16.7%), PAT ₹117 Cr (+24.6%). H1 growth is about 15%, yet management reiterates 20% for FY27, which needs a sharp H2 acceleration.
Privi Speciality Chemicals Ltd filed its quarterly shareholding pattern for the period ending 30 September 2026. Shareholding Pattern statements are routine regulatory disclosures with no transaction or business event.
Q2 FY27 total income Rs 773.16 Cr (+13.9%), EBITDA Rs 212.49 Cr (27.5% margin, +65bps), PAT Rs 117.03 Cr (+24.6%). H1 FY27 PAT +29.1%. Targets Rs 5,000 Cr revenue by FY29-30.
Privi Speciality Chemicals declared an interim dividend of Rs 5 per equity share for FY 2026-27 at its 29 October 2026 board meeting. Record date is 04 November 2026 and payment by 25 November 2026.
Privi Speciality Chemicals Ltd reported revenue from operations of ₹760.5 Cr (+12.1% YoY) and net profit of ₹117.5 Cr (+30.3% YoY) for Q2 FY27.
Privi Speciality Chemicals' NCLT-convened equity shareholder meeting approved the Scheme of Amalgamation of Privi Fine Sciences and Privi Biotechnologies into the company. The special resolution passed with requisite majority, subject to scrutinizer report.
Privi Speciality Chemicals intimated its board meeting is scheduled for October 29, 2026, to consider Q1/H1 results and an interim dividend. Items are proposed only and not yet decided.
Privi Speciality Chemicals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Privi Speciality Chemicals filed NCLT notice for an Oct 27, 2026 shareholders meeting on the amalgamation of Privi Fine Sciences and Privi Biotechnologies into it. No merger consideration value is stated.
SBI Mutual Fund sold 18,400 shares of Privi Speciality Chemicals Ltd via open market, reducing its stake from 7.3905% to 7.3434%.
Privi Speciality Chemicals announced an NCLT-convened meeting of equity shareholders for October 27, 2026, to consider the proposed Scheme of Amalgamation involving two transferor companies.
Privi Speciality Chemicals Ltd held its 41st Annual General Meeting on August 7, 2026. The meeting covered financial adoption, dividend declaration, and director appointments.
Privi reports 19.22% revenue growth and steady 24% EBITDA margins. Management maintains a confident outlook on expansion despite gross margin compression from high raw material costs compared to last year's low-cost base.
Privi reported strong Q1 FY27 results with 20.01% YoY revenue growth. Strategy focuses on '5k | 1k' vision via capacity expansion and higher-value specialty molecules.
Privi Speciality Chemicals Ltd reported revenue from operations of ₹666.2 Cr (+19.2% YoY) and net profit of ₹82.8 Cr (+43.7% YoY) for Q1 FY27.
Privi Speciality Chemicals Ltd has scheduled a Board Meeting on July 30, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Privi Speciality Chemicals dispatched a letter containing the Annual Report web-link for FY 2025-26. The 41st AGM is scheduled for August 07, 2026.
Privi Speciality Chemicals Ltd filed its FY 2025-26 BRSR, reporting a turnover of ₹2,056.25 Cr. The filing provides CSR and sustainability disclosures for investors.
Privi Speciality Chemicals Ltd scheduled its Annual General Meeting for 7 Aug 2026, proposing a final dividend of ₹10 per share. The meeting also ratified cost auditor remuneration of ₹0.09 Crore.
Privi Speciality Chemicals Limited announced its 41st Annual General Meeting on Friday, August 7 2026 at 4 pm IST. Remote e‑voting will run from August 4 to August 6, 2026.
Privi Speciality Chemicals received an 'AA Stable' credit rating from ICRA. This rating applies to its Rs.300 Crore long-term bank facility.
Privi reported strong FY26 performance with 22% revenue growth and 25.76% EBITDA margins, driven by volume growth and improved product mix.
Privi Speciality Chemicals Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory adherence with no material non-compliances noted.
Privi delivered strong FY26 performance with 22% revenue growth and 25%+ margins. Management is pivoting from a '5k revenue' goal to a more aggressive long-term trajectory via high-value specialty molecules and backward integration.
Privi Speciality Chemicals re-appointed Bhaktavatsala Rao Doppalapudi as Executive Director for three years. Internal and cost auditors were also re-appointed for one-year terms.
Privi Speciality Chemicals recommended a final dividend of ₹10 per equity share for FY 2025-26. The record date is set for July 31, 2026.
Privi Speciality Chemicals Ltd reported revenue from operations of ₹721.5 Cr (+17.6% YoY) and net profit of ₹94.1 Cr (+47.0% YoY) for Q4 FY26.
Privi Speciality Chemicals reported its audited FY26 financial results and recommended a 100% final dividend. The board also approved senior leadership re-appointments.
Privi Speciality Chemicals Limited received a 'no objection' observation letter from NSE for its merger scheme with Privi Fine Sciences and Privi Biotechnologies. Approval from BSE is currently awaited. The amalgamation remains subject to further regulatory and statutory clearances.
Privi Speciality Chemicals Limited has scheduled a board meeting for May 11, 2026, to consider audited financial results for the year ended March 31, 2026. The board will also evaluate a final dividend recommendation. The company's trading window is closed from April 1, 2026, until May 13, 2026.